La vendita allo scoperto per SPDR Portfolio Europe ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SPDR Portfolio Europe ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SPDR Portfolio Europe ETF (ARCA:SPEU), Report sulle vendite allo scoperto

Financial Services

Industrials

Healthcare

Technology

Consumer Cyclical

Consumer Defensive

Basic Materials

Energy

Communication Services

Utilities

Real Estate

Other

In seeking to track the performance of the STOXX Europe Total Market Index (the Index), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund. Based on its analysis of these factors, SSGA Funds Management, Inc. (SSGA FM or the Adviser), the investment adviser to the Fund, either may invest the Fund's assets in a subset of securities in the Index or may invest the Fund's assets in substantially all of the securities represented in the Index in approximately the same proportions as the Index, as determined by the Adviser to be in the best interest of the Fund in pursuing its objective. The Fund is classified as diversified under the Investment Company Act of 1940, as amended; however, the Fund may become non-diversified solely as a result of tracking the Index (e.g., changes in weightings of one or more component securities). When the Fund is non-diversified, it may invest a relatively high percentage of its assets in a limited number of issuers.

Novo Nordisk A/S B Common Stock Dkk.1

Asml Holding Nv

Nestle Sa

Astrazeneca Plc

Sap Se

Lvmh Moet Hennessy Louis Vuitton Se

Siemens Ag Reg

SPDR Portfolio Europe ETF

European,Central,Bank,President,Christine,Lagarde,Participates,In,A,Signing

News

Broad U.S. Equity ETFs

Eurozone

Emerging Market ETFs

Global

Econ #s

ETFs

DBEU

SPEU

La Banca Centrale Europea interviene nuovamente: quali sono le implicazioni per famiglie, imprese e mercati finanziari? Analisi e scenari.

La BCE taglia i tassi di interesse, è già la sesta volta in 9 mesi

Citigroup analyst Paul Diamond maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Sell and lowers the price target from $22 to $19.

Price Target

Analyst Ratings

Citigroup Maintains Sell on Magnolia Oil & Gas, Lowers Price Target to $19

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and lowers the price target from $320 to $280.

CVNA

Citigroup Maintains Buy on Carvana, Lowers Price Target to $280

Citigroup analyst Christopher Allen maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and lowers the price target from $84 to $75.

NDAQ

Citigroup Maintains Neutral on Nasdaq, Lowers Price Target to $75

General

BLNK

Blink Charging Receives Letter From Nasdaq Regarding Late Filing Of Form 10-K

Citigroup analyst Scott Gruber maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Buy and lowers the price target from $33 to $32.

Citigroup Maintains Buy on Helmerich & Payne, Lowers Price Target to $32

Unifirst Declares Regular Cash Dividends; New $100M Share Repurchase Authorization

Citigroup analyst Scott Gruber maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and lowers the price target from $54 to $53.

Citigroup Maintains Buy on Baker Hughes, Lowers Price Target to $53

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $423 to $375.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $375

Citigroup analyst Patrick Cunningham maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $135 to $113.

Citigroup Maintains Buy on PPG Indus, Lowers Price Target to $113

Citigroup analyst Patrick Cunningham maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy and lowers the price target from $99 to $84.

Citigroup Maintains Buy on Intl Flavors & Fragrances, Lowers Price Target to $84

NSYS

Nortech Systems Reveals New Patent For Non-Magnetic Expanded Beam Fiber Optic Cable Technology.

Citigroup analyst Patrick Cunningham maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Buy and lowers the price target from $305 to $275.

Citigroup Maintains Buy on Ecolab, Lowers Price Target to $275

Peabody Energy Announces It Is Reviewing All Options Regarding The Acquisition Of Steelmaking Coal Assets From Anglo American

Citigroup analyst Patrick Cunningham maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and lowers the price target from $95 to $74.

Citigroup Maintains Buy on DuPont de Nemours, Lowers Price Target to $74

Citigroup analyst Patrick Cunningham maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Neutral and lowers the price target from $42 to $32.

AXTA

Citigroup Maintains Neutral on Axalta Coating Systems, Lowers Price Target to $32

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Legal

JAZZ

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Nio Files 2024 Annual Report On Form 20-F For FY24 With The SEC

Citigroup analyst Christopher Allen maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Neutral and lowers the price target from $55 to $39.

Citigroup Maintains Neutral on Carlyle Group, Lowers Price Target to $39

Citigroup analyst Chris Allen maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $177 to $132.

Citigroup Maintains Buy on KKR, Lowers Price Target to $132

Citigroup analyst Chris Allen maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and lowers the price target from $190 to $137.

Comments

SPDR Portfolio Europe ETF

Vendite allo scoperto

SPDR Portfolio Europe ETF (ARCA:SPEU), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO